Abstract
TRPM8 activation increased susceptibility to spreading depolarization (SD) and facilitated the effects of CGRP and trigeminal neuroinflammation, implicating that TRPM8 may contribute to migraine pathophysiology through central and peripheral mechanisms.
Introduction
Migraine is a complex neurological disorder characterized by debilitating headaches and, in many cases, aura. Genome-wide association studies (GWAS) have consistently linked the TRPM8 gene—which encodes a cold-sensing ion channel—to migraine susceptibility. However, the functional role of TRPM8 has remained controversial. While some patients find relief through cold therapy, others report cold weather as a primary trigger. This study investigates the dual role of TRPM8 in two key migraine hallmarks: Spreading Depolarization (SD), the electrical wave underlying aura, and Trigeminal Neuroinflammation, the inflammatory process driving headache pain.
Methodology
The researchers utilized Sprague-Dawley rat models to assess TRPM8's effects across different scales:
- Central Assessment (In Vivo): TRPM8 agonists (icilin) and antagonists (M8-B) were administered to the brain (i.c.v. or topically) to measure the frequency and duration of KCl-evoked SD events.
- Peripheral Assessment (In Vitro): Primary cultures of rat trigeminal ganglion (TG) cells were established to study head pain signaling.
- Molecular Mapping: The team employed Fura-2 calcium imaging to track ion flow, ELISA for CGRP quantification, and Western Blotting/Immunostaining for inflammatory markers like Cox2 and TNF-α.
Key Results
1. Increased SD Susceptibility
In the cerebral cortex, TRPM8 is expressed almost exclusively in neurons. Activating these central receptors with icilin (50–500 μM) significantly increased the frequency of SD events. This suggests that TRPM8 lowers the threshold for the brain to enter the "aura" state. Interestingly, inhibiting TRPM8 with M8-B did not alter baseline SD frequency, indicating the channel is not constitutively active under normal conditions.
2. Trigeminal Neuroinflammation and CGRP Release
In the peripheral trigeminal system, TRPM8 activation triggered a rapid 13% increase in intracellular calcium within TG cells. This influx led to a dose-dependent release of Calcitonin Gene-Related Peptide (CGRP), a key peptide in migraine pain. Furthermore, TRPM8 activation exacerbated SD-induced neuroinflammation, significantly increasing levels of Cox2 and TNF-α.
3. The CaMKII Signaling Pathway
The study identified a clear biochemical relay: TRPM8 activation leads to calcium influx, which activates the Calcium/calmodulin-dependent protein kinase II (CaMKII) pathway. This pathway, in turn, drives CGRP release and Cox2 upregulation. The use of the inhibitor KN-93 successfully blocked these effects, confirming the pathway's involvement.
Discussion and Limitations
These findings provide a mechanistic explanation for how a cold-sensing receptor contributes to migraine. By increasing SD susceptibility centrally and driving CGRP release peripherally, TRPM8 acts as a bridge between environmental triggers and the brain's pain machinery.
However, several questions remain. The study was conducted exclusively on male rats, leaving potential sex-dependent differences—crucial in a female-predominant disease like migraine—unexplored. Additionally, while icilin is a potent agonist, future research using genetic knockout models is needed to confirm absolute specificity. Finally, identifying the endogenous ligands that activate TRPM8 internally (such as the growth factor artemin) will be essential for developing targeted therapies.
Summary updated